Stents Vs. Balloons Question For Peripheral Artery Disease Gets Attention At Veith
This article was originally published in The Gray Sheet
Executive Summary
The presence of the first drug-eluting stent on the U.S. market to treat peripheral artery disease is certainly not the end of the discussion for how peripheral artery patients will be treated, clinicians made clear at the influential Veith Symposium this month.
You may also be interested in...
Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents
One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.
Drug-Coated Balloons Fuel Multibillion-Dollar Hopes
With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.
New Products In Brief
Recent approvals and launches include Cook’s Zilver PTX drug-eluting stent for peripheral arterial disease, Medtronic’s Valiant Captivia stent graft system and Cordis’ S.M.A.R.T. Control vascular stent.